Concepedia

S. Hüttner

SH

Statistics

Publications

4

Citations

367

H-Index

4

Active since

2008

Affiliations

Boehringer Ingelheim (Germany)(Current)

S. Hüttner is an author at Boehringer Ingelheim (Germany) specializing in dipeptidyl peptidases, pharmacodynamics, and clinical pharmacology.

Publications per year

2008–2022

4

Publications

4

Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase‐4 inhibitor in male type 2 diabetes patients

Tim Heise, Eva U. Graefe-Mody, S. Hüttner et al. · Diabetes Obesity and Metabolism · 2009 · 175 citations

, , +16

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Oral Doses of BI 1356, an Inhibitor of Dipeptidyl Peptidase 4, in Healthy Male Volunteers

S. Hüttner, Eva U. Graefe-Mody, B. Withopf et al. · The Journal of Clinical Pharmacology · 2008 · 133 citations · Full text

, , +13

Pharmacokinetics and Pharmacodynamics of Single Rising Intravenous Doses (0.5 mg–10 mg) and Determination of Absolute Bioavailability of the Dipeptidyl Peptidase-4 Inhibitor Linagliptin (BI 1356) in Healthy Male Subjects

Silke Retlich, Vincent Duval, Arne Ring et al. · Clinical Pharmacokinetics · 2010 · 48 citations

, , +10

Phase 1 and 2 Randomized Clinical Studies Determine Lack of Efficacy for Anti-IL-17C Antibody MOR106 in Moderate–Severe Atopic Dermatitis

Diamant Thaçi, Dave Singh, Mark S. Lee et al. · Journal of Clinical Medicine · 2022 · 11 citations · Full text

, , +17

1–4 of 4